Global Amyotrophic Lateral Sclerosis Treatment Market

Global Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth Analysis, By Treatment(Meditation, Stem Cell Therapy), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies) - Industry Forecast 2023-2030


Report ID: SQMIG35J2089 | Region: Global | Published Date: February, 2024
Pages: 242 | Tables: 65 | Figures: 75

Global Amyotrophic Lateral Sclerosis Treatment Market Insights

Global Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 647.9 million in 2021 and is poised to grow from USD 685.48 million in 2022 to USD 1138.58 million by 2030, growing at a CAGR of 5.8% in the forecast period (2023-2030).

Amyotrophic lateral sclerosis (ALS), also have different names such as Charcot diseases, Lou Gehrig diseases, Motor neuron diseases. ALS is a progressive neurodegenerative disorder that damage the nerve cell in central nervous system responsible for controlling the voluntary muscles. Some of the common symptoms include muscle twitching, stiff muscles, and weakness due to a decrease in the size of muscles of the legs or arms. Around half of the people suffering from ALS may lose the ability to swallow, breathe, speak, walk, and use their hand.

According to the National Institute of Neurological Disorders and Stroke (NINDS), following gradual paralysis, patients with ALS often die from respiratory failure within 3-5 years. It also states that between the two types of ALS, the sporadic type is the most common form, accounting for 90-95% of all cases in the U.S. while the familial type accounts for the rest. Familial ALS (FALS) is hereditary, where there is a 50% chance of inheriting the genetic mutation for each offspring and eventually developing the disorder. In 25-40% of the people suffering from familial ALS, the defect is most commonly found in the C9ORF72 gene. Mutation in this gene also leads to a condition known as frontotemporal dementia (FTD), which may develop along with ALS as comorbidity referred to as ALS-FTD.

Although there is no cure for ALS, treatments such as medications and stem cell therapies can help in the management of the symptoms, prevention of unnecessary complications and slow down the disease progression. These factors are expected to further drive the global amyotrophic lateral sclerosis treatment market growth.

US Amyotrophic Lateral Sclerosis Treatment Market is poised to grow at a sustainable CAGR for the next forecast year.

To get more reports on the above market click here to Buy The Report

Global Amyotrophic Lateral Sclerosis Treatment Market Segmental Analysis

Global amyotrophic lateral sclerosis treatment market is segmented based on treatment, distribution channel, type, and region. On the basis of treatment, it is segmented into medication, stem cell therapy, others. On the basis of distribution channel, the global amyotrophic lateral sclerosis treatment market is segmented into hospital pharmacies, retail pharmacies, others (online pharmacies, diagnostics laboratories and clinics). Based on type, it is segmented as Sporadic ALS, Familial ALS. Based on the region, it is segmented as North America, Europe, Asia Pacific, and Middle East and Africa.

Amyotrophic Lateral Sclerosis Treatment Market Analysis by Treatment

The meditation segment dominated the global amyotrophic lateral sclerosis treatment market. It dominates the global ALS treatment market through the forecast period. There are only two drugs approved for the treatment of ALS Rilutek (riluzole), and Radicava (edaravone). Another drug, Nuedexta (dextromethorphan/quinidine) received FDA approval for the treatment pseudobulbar affect (PBA), comorbidity of ALS.

Stem cell therapy is expected to show the highest CAGR due to the increasing demand for new approaches and advanced treatment options. A number of initiatives have been launched by government agencies and the Collaborative ALS Drug Discovery Initiative (CADDI) to accelerate the development of new drugs and treatments. This is expected to increase the number of clinical trials and pipeline drug launches during the forecast period.

Amyotrophic Lateral Sclerosis Treatment Market Analysis by Distribution Channel

Hospital pharmacies accounted for the largest market share and expected to retain leading position during the forecast period. It is followed by retail pharmacies and then others. The requirement for several hospital stays and visits during ALS treatment facilitates the growth of this segment. There is high patient preference for hospital pharmacies as well as retail pharmacies. This can be attributed to the easy and rapid access to a broad range of drugs and adequate products in the stock offered by these distribution channels.

Online Pharmacies are also gaining prominence due to the growing popularity of e-commerce channels that offer a wide range of options along with in-depth drug information.

To get detailed analysis on other segments, Request For Free Sample Report

Global Amyotrophic Lateral Sclerosis Treatment Market Regional Insights

North America had the largest market share in 2018 and is expected to maintain that position throughout the forecast period. The factors driving the market are high healthcare expenditure, favorable reimbursement policies, high demand for ALS drugs, and established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, approximately 16,583 cases of amyotrophic lateral sclerosis were identified in the United States in 2015.

Over the forecast period, Asia Pacific is expected to grow at the fastest rate of all regions. This region's riluzole generic manufacturers are increasing their revenue generation, particularly in India and China. Growing R&D investment in the healthcare sector, a plethora of untapped opportunities, and promising initiatives by manufacturers and governments are some of the key factors driving market growth in this region.

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Amyotrophic Lateral Sclerosis Treatment Market Dynamics

Amyotrophic Lateral Sclerosis Treatment Market Driver

  • Global amyotrophic lateral sclerosis treatment market is projected to be driven by a rise in prevalence of amyotrophic lateral sclerosis disease. According to the Centers for Diseases Control and Prevention (CDC), in 2016, between 14,500 and 15,000 people in the U.S. had amyotrophic lateral sclerosis, of these about 5,000 people are diagnosed annually. Globally, about 2 – 5 people in every 100,000 are affected by ALS. Additionally, inclination toward sedentary lifestyle and increase in the geriatric population fuel the demand for targeted and symptomatic treatment options. This is expected to drive the market during the forecast period.

Amyotrophic Lateral Sclerosis Treatment Market Restraint

  • High cost of treatment, less awareness about amyotrophic lateral sclerosis diseases, and limited availability of treatment option are likely to hamper the market during the forecast period. Amyotrophic lateral sclerosis is so rare that treatment can be prohibitively expensive. Edaravone is a common drug or active ingredient used to treat ALS because it aids in the elimination of free radicals that cause neuron damage. This drug can cost around $145,000 per year. With other costs such as hospital bills, the entire treatment could cost around $200,000. Furthermore, there is no guarantee that such treatments will improve a patient's condition. As a result, even after spending thousands of dollars, very low survival rates can be a significant setback in the growth of the respective market.

Request Free Customization of this report to help us to meet your business objectives.

Global Amyotrophic Lateral Sclerosis Treatment Market Competitive Landscape

Global amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F. Hoffmann-La Roche AG.

Top Players in Global Amyotrophic Lateral Sclerosis Treatment Market

  • Mitsubishi Tanabe Pharma Corporation
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Sanofi S.A.
  • Genentech Inc.
  • Cytokinetics Inc.
  • Avanir Pharmaceuticals, Inc.
  • Novartis International AG
  • Ionis Pharmaceuticals, Inc.
  • Neuraltus Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Anavex Life Sciences Corp.
  • AB Science
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • GW Pharmaceuticals plc
  • Mitsubishi Chemical Corporation
  • Regeneron Pharmaceuticals Inc.
  • Biocytogen, LLC.

Amyotrophic Lateral Sclerosis Treatment Market Recent Developments

  • In June 2022, Canada approved Amylyx Pharmaceuticals Inc.’s new drug ALBRIOZA (also known as AMX0035) for amyotrophic lateral sclerosis.
  • In May 2022, Mitsubishi Tanabe Pharma America received the United States Food and Drug Administration Approval for RADICAVA ORS (edaravone) for the Treatment of amyotrophic lateral sclerosis.
  • On April 2020, LonisPharma established a 25,000 scholarship to help ALS patients in the greater San Diego area participate in physical and mental wellness programs.

Global Amyotrophic Lateral Sclerosis Treatment Key Market Trends

  • Due to the hectic schedule of the individual and changing lifestyle there is rising incidences of neurodegenerative disorders which is driving the global amyotrophic lateral sclerosis treatment market. Beside this, expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGO and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted symptomatic treatment options for ALS is acting as a significant growth-inducing factor.
  • Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering market growth. Moreover, increasing strategic collaboration among various research institute to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalysing the global market.

Global Amyotrophic Lateral Sclerosis Treatment Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, rise in the incidence of amyotrophic lateral sclerosis is expected to accelerate market growth from 2022 to 2028. Increased geriatric population and increased awareness of amyotrophic lateral sclerosis are also expected to boost the amyotrophic lateral sclerosis treatment market growth. Furthermore, the rise in the launch of novel medicines, as well as an increase in healthcare expenditure and well-established healthcare infrastructure, are expected to drive market growth.

Report Metric Details
Market size value in 2021 USD 647.9 million
Market size value in 2030 USD 1138.58 million
Growth Rate 5.8%
Base year 2021
Forecast period 2023-2030
Forecast Unit (Value) USD Million
Segments covered
  • Treatment
    • Meditation, Stem Cell Therapy, Others.
  • Distribution Channel
    • Hospital Pharmacies, Retail Pharmacies, Others (online pharmacies, diagnostics laboratories, clinics).
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Mitsubishi Tanabe Pharma Corporation
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Sanofi S.A.
  • Genentech Inc.
  • Cytokinetics Inc.
  • Avanir Pharmaceuticals, Inc.
  • Novartis International AG
  • Ionis Pharmaceuticals, Inc.
  • Neuraltus Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Anavex Life Sciences Corp.
  • AB Science
  • Biohaven Pharmaceutical Holding Company Ltd.
  • Ono Pharmaceutical Co., Ltd.
  • Bausch Health Companies Inc.
  • GW Pharmaceuticals plc
  • Mitsubishi Chemical Corporation
  • Regeneron Pharmaceuticals Inc.
  • Biocytogen, LLC.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Amyotrophic Lateral Sclerosis Treatment Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Amyotrophic Lateral Sclerosis Treatment Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Amyotrophic Lateral Sclerosis Treatment Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Amyotrophic Lateral Sclerosis Treatment Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Amyotrophic Lateral Sclerosis Treatment Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Amyotrophic Lateral Sclerosis Treatment Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 647.9 million in 2021 and is poised to grow from USD 685.48 million in 2022 to USD 1138.58 million by 2030, growing at a CAGR of 5.8% in the forecast period (2023-2030).

Global amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F. Hoffmann-La Roche AG. 'Mitsubishi Tanabe Pharma Corporation', 'BrainStorm Therapeutics', 'Biogen Inc.', 'Sanofi S.A.', 'Genentech Inc.', 'Cytokinetics Inc.', 'Avanir Pharmaceuticals, Inc.', 'Novartis International AG', 'Ionis Pharmaceuticals, Inc.', 'Neuraltus Pharmaceuticals, Inc.', 'Pfizer Inc.', 'Anavex Life Sciences Corp.', 'AB Science', 'Biohaven Pharmaceutical Holding Company Ltd.', 'Ono Pharmaceutical Co., Ltd.', 'Bausch Health Companies Inc.', 'GW Pharmaceuticals plc', 'Mitsubishi Chemical Corporation', 'Regeneron Pharmaceuticals Inc.', 'Biocytogen, LLC.'

Global amyotrophic lateral sclerosis treatment market is projected to be driven by a rise in prevalence of amyotrophic lateral sclerosis disease. According to the Centers for Diseases Control and Prevention (CDC), in 2016, between 14,500 and 15,000 people in the U.S. had amyotrophic lateral sclerosis, of these about 5,000 people are diagnosed annually. Globally, about 2 – 5 people in every 100,000 are affected by ALS. Additionally, inclination toward sedentary lifestyle and increase in the geriatric population fuel the demand for targeted and symptomatic treatment options. This is expected to drive the market during the forecast period.

Due to the hectic schedule of the individual and changing lifestyle there is rising incidences of neurodegenerative disorders which is driving the global amyotrophic lateral sclerosis treatment market. Beside this, expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth. Furthermore, several NGO and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted symptomatic treatment options for ALS is acting as a significant growth-inducing factor.

North America had the largest market share in 2018 and is expected to maintain that position throughout the forecast period. The factors driving the market are high healthcare expenditure, favorable reimbursement policies, high demand for ALS drugs, and established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, approximately 16,583 cases of amyotrophic lateral sclerosis were identified in the United States in 2015.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Amyotrophic Lateral Sclerosis Treatment Market

Product ID: SQMIG35J2089

$5,300
BUY NOW GET FREE SAMPLE